Sarah Larson, MD

The medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA).

Articles by Sarah Larson, MD

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)

Evaluating Lyell’s CAR-T IMPT-314 in LBCL

BySarah Larson, MD,Noah Stansfield

January 28th 2025

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.

Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL

BySarah Larson, MD,Noah Stansfield

January 24th 2025

The medical director of the Immune Effector Cell Therapy Program at UCLA discussed initial data from a phase 1/2 trial.

Sarah Larson, MD

Articles by Sarah Larson, MD

Evaluating Lyell’s CAR-T IMPT-314 in LBCL

Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL

Latest Updated Articles

Trending on CGTlive®

Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial

Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation

Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025

FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program

Guess the Therapy Answer October 16, 2025